Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 50.88% is in line with its 2-year average of 52.92%, around the middle of its 2-year range (47.60%–56.00%).
1.23% below its 12-month average of 51.51%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 51.36%.
GROSS MARGIN
50.88%
GROSS MARGIN AVG TTM
51.51%
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.23%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+22.96%
vs the sector median at left
Market Cap
$322.71M
Gross Margin
81.56%
TTM Avg
83.99%
3Y Avg
83.73%
5Y Avg
82.68%
Market Cap
$321.76M
Gross Margin
91.33%
TTM Avg
90.37%
3Y Avg
88.70%
5Y Avg
89.14%
Market Cap
$330.19M
Gross Margin
62.61%
TTM Avg
61.15%
3Y Avg
61.24%
5Y Avg
64.05%
Market Cap
$318.43M
Gross Margin
77.81%
TTM Avg
88.91%
3Y Avg
85.13%
5Y Avg
50.71%
Market Cap
$309.19M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
25.00%
5Y Avg
13.20%
Market Cap
$344.04M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CapsoVision, Inc. (CV) | $324.76M | 50.88% | 51.51% | N/A | N/A |
| Avita Medical Inc. (RCEL)vs › | $322.71M | 81.56% | 83.99% | 83.73% | 82.68% |
| Sanara MedTech Inc. (SMTI)vs › | $321.76M | 91.33% | 90.37% | 88.70% | 89.14% |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | 62.61% | 61.15% | 61.24% | 64.05% |
| C4 Therapeutics, Inc. (CCCC)vs › | $318.43M | 77.81% | 88.91% | 85.13% | 50.71% |
| Agenus Inc. (AGEN)vs › | $311.90M | 29.63% | -10.58% | -43.61% | -33.41% |
| Benitec Biopharma Inc. (BNTC)vs › | $309.19M | 0.00% | 0.00% | 25.00% | 13.20% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.04M | 0.00% | 0.00% | 0.00% | 0.00% |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
50.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 51.36% |
| 2026-03-31 | 47.60% |
| 2025-12-31 | 49.87% |
| 2025-09-30 | 54.10% |
| 2025-06-30 | 54.63% |
| 2025-03-31 | 53.68% |
| 2024-12-31 | 50.23% |
| 2024-09-30 | 55.87% |
| 2024-06-30 | 56.00% |
| 2024-03-31 | 55.87% |
